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Enabling technologyThe development of cell based advanced therapeutic medicinal products (ATMPs) for bone repair has been ex-
pected to revolutionize the health care system for the clinical treatment of bone defects. Despite this great prom-
ise, the clinical outcomes of the few cell basedATMPs that have been translated into clinical treatments have been
far from impressive. In part, the clinical outcomes have been hampered because of the simplicity of the first wave
of products. In response the field has set-out and amassed a plethora of complexities to alleviate the simplicity
induced limitations. Many of these potential second wave products have remained “stuck” in the development
pipeline. This is due to a number of reasons including the lack of a regulatory framework that has been evolving
in the last years and the shortage of enabling technologies for industrial manufacturing to deal with these novel
complexities. In this review, we reflect on the current ATMPs and give special attention to novel approaches that
are able to provide complexity to ATMPs in a straightforward manner. Moreover, we discuss the potential tools
able to produce or predict ‘goldilocks’ ATMPs, which are neither too simple nor too complex.
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The ability to create well characterized cell based advanced
therapeutic medicinal products (ATMPs) is expected to play a crucial
role to fulfill the needs of the ever growing demand for biologically
functional bone grafts. In the year 2008 there were half a million
patients in the United States in which a bone defect was repaired. This
resulted in a health care burden of over $2.5 billion. It is expected that
by the year 2020 these numbers have doubled [1]. It is expected of
ATMPs to repair, replace and/or regenerate damaged or missing tissue,
thereby complementing current therapeutic options or even provide
treatments for currently untreatable pathologies in a cost-effective
manner. For bone healing in particular, it is mainly expected to prevent
or heal non-unions and thereby reduce the long term cost of patient
care.
The development of these desired cell based ATMPs is typically
based on three basic elements: biomaterials, cells and growth
factors. Ideally, the chosen combination of the biomaterial and growth
factors should form a biomimetic environment that drives the cells
into the formation of a new functional tissue [2]. As such, the develop-
ment of ATMPs is a multidisciplinary process that requires expertise
from several disciplines including biology and engineering. Biology
provides crucial information on the underlying molecular signaling
mechanisms and understanding of cellular behavior. Engineering is
then employed to mimic these processes, therefore also denominated
as developmental engineering [3,4]. This can be achieved in several
ways including by creating a mechanical support that provides a
stimulating microenvironment via a spatiotemporal release of choice
molecules and facilitates integration within the host. Moreover, funda-
mental knowledge in physiology, biochemistry, and biomechanics pro-
vides additional information on the design criteria of the envisioned
ATMPs.
Many bio-inspired elements have been incorporated in cell based
ATMPs. However, their spatial distribution has typically remained
homogenous. In fact, much effort has been dedicated to distribute cells
and growth factors as homogeneously as possible throughout the
biomaterial [5]. This homogeneity based approach can be argued to be
advantageous from the perspective that it provides a facile, elegant
and industrially attractive process to produce cell based ATMPs.
However, this elementary and uncomplicated approach comes at a
cost. The architecture of natural tissues is not homogeneous. Instead it
is characteristically marked by a systematic “heterogeneity”. In fact, it
is typically rather an assembly of repetitive smaller building blocks
that are present on the nano-, micro- and macro-scale, and organized
into a specific tissue/anatomical structure. Regarding bone, a well
known example is represented by the organization of collagen, bone
marrow niche, osteons and trabeculae. Moreover, most natural tissues
including bone contain a complex, repetitive and ever-finer network
of blood vessels. These heterogeneous yet repetitive designs are
not only of great importance to the archetypal structure of tissues, but
are essential for their function. In consequence, ATMPs that are too
elementary and uncomplicated are expected to result in reduced tissue
behavior and display limitations with regard to tissue integration,
functionality and turnover, and thus will be characterized by reduced
potential clinical outcomes.
In recent years ever more sophisticated methodologies have been
pioneered to give rise to the desired biological sophistication within
ATMPs [6]. However, this too comes at a cost as it potentially requires
the sacrifice of a straightforward approach. Specifically, the newly ac-
quired complexity might improve the ATMP clinical performance, but
reduces the clinical feasibility.
In this review, we reflect on the complexity level of current ATMPs
and give special attention to novel approaches that are able to provide
complexity to ATMPs in a straightforward manner. Moreover, we dis-
cuss the potential tools able to produce or predict ‘goldilocks’ ATMPs,
which are neither too simple nor too complex.Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.10.0252. Mechanisms of bone formation
2.1. Natural bone healing
To understand how cell based ATMPs could effectively repair or re-
generate bone tissue, it is of importance to understand the natural
bone healing process. In fact, bone has a remarkable potential for repair,
albeit with finite capabilities. Upon fracture the bone develops a hema-
toma that is followed by two distinct bone formation processes (Fig. 1).
Themost intuitive form of bone formation is intramembranous ossi-
fication in which the osteoblasts directly produce and deposit woven
bone. This process typically takes place at the more peripheral sites of
the hematoma. The newly formedwoven bone contributes to the filling
of the defect and thereby able to provide some mechanical stability.
However, due to the unordered (or unorganized) disposition of
the fiber, woven bone provides only limited mechanical support. The
newly formed bone is then slowly remodeled into the strong and well
organized lamellar bone via awell-orchestrated interplay of osteoclastic
resorption and bone matrix deposition by osteoblasts.
The second process by which our body is able to form bone is via
endochondral ossification. In this process bone is formed via a distinct
intermediary cartilaginous tissue. During fracture healing, the oxygen
tension within the large center mass of the hematoma strongly
decreases. This activates the signaling machinery that allows cells to
cope with hypoxic environments. Importantly, this response also trig-
gers chondrogenic differentiation of residing and/or recruited progeni-
tor cells. The newly formed cartilage is able to survive the hypoxic
stress and contribute to the stabilization of the fractured bone. The car-
tilage continues to mature until it reaches a terminally differentiated
stage, which is characterized by chondrocyte hypertrophy, cartilage
catabolism, matrix calcification and angiogenesis. The infiltrating
blood vessels relieve the hypoxic stress and thereby reinforce the ongo-
ing hypertrophic differentiation as well as deliver tissue forming cells
such as osteoblasts to it [7]. These cells then form lamellar bone on
the recently mineralizedmatrix allowing the tissue to regain its original
strength. The rate, quantity and quality of the various stages of bone
healing are highly influenced by a myriad of factors, which include the
age and health of the patients, the type of bone, the location and type
of fracture, mobility of the fracture site, available blood supply and
infection in or near the fracture site. As such, it can be considered that
a detailed diagnostic phase followed by meticulous patient selection
can play an important role in the successful development of ATMPs.
2.2. Controlling the cell fate of cell based ATMPs
Inspired by natural bone healing, cell based ATMPs for bone repair
are thus optimized for either intramembranous ossification or endo-
chondral ossification. Full mastery over the progenitor cell's osteogenic
and chondrogenic differentiation processes and behaviors is therefore
of the utmost importance. The cell specification and differentiation
mechanisms are underpinned by a complex yet elegant interplay of
several signaling pathways. These processes and interactions occur in
a highly dynamic fashion in which a single signaling mechanism can
even play either stimulating or inhibiting roles depending on the differ-
entiation stage of the cell [8].
Fortunately, control over these complex processes can be achieved
in a relatively simple manner as they are governed by a limited set of
master regulators (Fig. 2). For example, activation of WNT and RUNX2
signaling in mesenchymal progenitor cells results in osteogenesis and
subsequent intramembranous ossification [9]. WNT and RUNX2 also
contribute to endochondral ossification by driving chondrocytes into
hypertrophic differentiation. In short, the ATMP's cell fate can most
likely be controlled by presenting a limited set of biomimetic factors
that initiate a cascade of events that allow the cell's own molecular
machinery to progress in differentiation status in a semi-autonomous
manner.medicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
Fig. 1. Schematic overview of the natural healing process of long bones.
Adapted from [194].
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Despite the great promise that regenerative medicine approaches
will change the way we deal with damaged tissues in clinics including
the gearing ofmedical practice towards personalizedmedicine, the clin-
ical achievements are far from impressive. This has cast a shadow over
the substantial investments in the field over the last decade. During
this time, a few cell based ATMPs for joint surface and skinwound repair
have reached themarket. However, their results are not yet reaching the
original expectations and are strongly dependent on the patient profile.
Moreover,manypotential applications have remained “stuck” in thede-
velopment pipeline. This is due to a number of reasons including the
lack of a regulatory framework that has been evolving in the last
years, the lack of understanding of how the cell based ATMPs contribute
to a good clinical outcome, the need for long term follow-up, and the
shortage of enabling technologies for industrial manufacturing. In con-
sequence, the designs of the first wave of products have been relatively
elementary and uncomplicated, which have hampered the obtainment
(or achievement) of better clinical outcomes.
As a result of the limitations of the first wave, new approaches have
been proposed. These are mainly focused on the altered strategy to
translate ATMPs more explicitly using a so called developmental engi-
neering approach,which incorporates biomimetic elements and follows
the principles of natural tissue formation. Mimicking in full the com-
plete natural processes, however, will take time and the development
of new enabling technologies will be an ongoing process for the coming
decades. In spite of this, there is a very reasonable chance that
somewhat more elementary and uncomplicated approaches, not fullyFig. 2. Schematic overview of the two possible differentiationmechanisms of progenitor cells to
colored in red are down regulated.
Adapted from [195].
Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.10.025mimicking nature, but respecting and incorporating normal physiolog-
ical processes may be sufficient to obtain tissue intermediates or provi-
sional tissues with very acceptable clinical results in well-defined
patient populations. To achieve this additional dimension of ATMPs, it
is imperative to improve our manufacturing technologies so that one
can robustly produce ATMPs at an industrial dimension. Steps are
taken to improve the manufacturing of the essential hardware, cells,
stimulating factors and biomaterials. With these tools in place it is pos-
sible to bring the tissue engineering process in a new dimension. Some
of these aspects are discussed below and present a vision on how com-
plexity can be incorporated into cell based ATMPs to – hopefully –
achieve better clinical outcomes inmany applications. It is an important
side note that, as it is envisaged that more robust products will enter
clinics, also the clinicians will play an active role in the selection and
further development of the cell based ATMPs. Indeed, the behavior of
cell based living ATMPs is strongly influenced by its environment,
and thus the patient's exact condition. Therefore, well defined patient
populations will be critical for the successful clinical translation of
novel cell based ATMPs.
4. Recent developments to improve ATMPs: complexity induced
progress
Cell based ATMPs have relied on a classical toolset to control the
cell's fate by targeting the aforementioned set of key factors to mimic
the natural tissue forming process. Historically, this tool set is comprised
of the selection and modification of a biomaterial, the pre-selection
and incorporation of specific tissue forming cells and the inclusion andcontribute to the formation ofnew bone. Factors colored in green are up regulated. Factors
medicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
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importance to note that, although each of these factors can provide a
specific desired effect, their final contribution is heavily affected by
co-selected factors. For example, the performance of a specific growth
factor can strongly vary when included in biomaterials with different
release curves or when presented to different (progenitor) cells able
to form a similar tissue [10].
4.1. Biomaterials: from scaffold to bio-instructive microenvironment
Over the last decades many biomaterials suitable for bone tissue
engineering applications have been described. These biomaterials can
be divided into six general classes: bioceramics, bioactive glasses, bio-
polymers, metals, self-assembly peptides and (decellularized) extracel-
lular matrices (Supplementary Table 1). Each contains members that
are biocompatible, biodegradable and/or with strong mechanical prop-
erties. Importantly, all classes have been modified to contain bone-
stimulating components, with the aim to mimic the physicochemical
characteristics of natural bone tissue.
Biomaterials designed for bone tissue engineering most commonly
rely on collagen-like fibers and/or hydroxyapatite-based materials
(e.g. animal-derived bone chips or synthetic calcium phosphate) to
facilitate bone growth (osteoconduction) [11]. Other similar material
classes such as corals, bioactive glasses, and polymers are used – or
blendedwith the former – to produce scaffoldswith improvedmechan-
ical strength, remodel rates, and osteogenic properties including the
capability to actively induce bone formation (osteoinduction) [12,13]. In
recent years, the use of hydrogels has grown significantly in popularity.
Hydrogels are biopolymers that are archetyped by their high water con-
tent, thereby resembling the natural in vivo milieu of mammalian cells.
This has been demonstrated to be beneficial for tissue morphogenesis
[14,15]. In contrast, biocompatible metallic scaffolds have unsurpassed
mechanical strength and are able to provide precise patient-customized
geometries and features [16].
The aforementioned biomaterial classes constitute the basic ground
substances for the design of novel cell based ATMP. However, merely
using these biomaterials in their unmodified form has proven to be
insufficient to achieve satisfying clinical outcomes. In consequence,
the real challenge is to obtain proper physical micro- and nano-
topographies [17,18] on the surface of a biomaterial in combination
with the conjugation of biochemical cues that are released at
physiologically-stimulating concentrations, and matching this with
the dynamics of tissue healing and regeneration processes to facili-
tate bone growth [19].
Translating existing biomaterials into effective bone healing thera-
pies still remains a challenge as the biomaterials are required to satisfy
both the mechanical and biological context of living bone. This can
be witnessed in the attempts to effectively vascularize clinically sized
implants [20]. Indeed, successful human clinical trials – using stem cell
laden biomaterials – have emphasized on their implant's capability to
recruit vasculature and robustly integrate within the host [21,22].
From these studies several lessons can be learned. First and foremost,
cell based ATMPs should be designed to control, or at least provide,
cell–material interactions. This can amongst others be achieved by
modifying the biomaterial to contain specific topographical features,
which can be fabricated in an either monotonic or graded fashion [23].
Providing such topographical features can dramatically improve cellular
adhesion through focal adhesion formation via forced integrin cluster-
ing. This can be also be achieved via e.g. micro- and nanoscale protru-
sions, pits and grooves [24]. Moreover, such topographies can also
provide instructive roles for biomaterial-controlled differentiation of
progenitor cells. For example, specific features stimulate mesenchymal
stromal cells to undergo osteogenic differentiation as effectively as
growth factor containing osteogenic media [25]. Moreover, surface
roughness at the resorption sealing zone is sensed by osteoclasts
through forces applied at varying heights and angles of the surfaces.Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.10.025Indeed, submicrometer cracks (0.1–1 μm range) stimulate local
osteoclast resorptive activity [26]. Providing biomaterials with these
modified surfaces is also known to be crucial to enhance implant
integration and bone healing [27].
Biomaterials characteristics can also be fine-tuned by modifying the
material chemical properties and/or “decoration” with biological cues.
This can be achieved either exogenously by adding growth factors, cell
adhesion peptides and enzymes or by adding surface charges to entrap
proteins or growth factors upon implantation. In this perspective, the
refinement in the production process of calcium-phosphate (CaP)-
based biomaterials has beenwell-developed. Specifically, it can be opti-
mized using specific crystallinity,macro- andnano-porosity, concavities
and ion dissolution kinetics to direct cellular behavior and tissue forma-
tion [28,29]. Biomaterials can be further decorated with biological cues
by incorporation of growth factors via molecular linkage [30]. Growth
factors can be bound to polymer backbones [31,32], coated on scaffold
surfaces [33] or soaked into scaffolds [34,35]. These proteins or peptides
typically target bone forming pathways or vasculature forming path-
ways [36]. In addition, the angiogenic process and the concomitantly
ingrowing vessels are believed to precede and dictate the architecture
of the newly formed bone in a positive manner [37].
Besides the attempts to recreate micro- and nano-scale topographi-
cal and biological cues from the bone extracellular environment, the
latest generation of biomaterials contains biomimetic nucleation
motifs/sites that promote mineralization. For example, through the
use of enzymes, single-molecule templates and bi-/multi-molecular
template systems that promote physiological and hierarchical self-
assembly of bone apatite and proteins [38]. These recent developments
are applications of the rapidly progressing field of self-assembly peptide
scaffolds. These provide bio-instructive supramolecular cues that
effectively mimic the hierarchical ordered nanostructures of the ECM,
which facilitates mineralization, epitope-presentation for modulation
of cell behavior and delivery of protein and small molecules [39].
In summary, in recent years the complexity of novel cell based
ATMPs has increased very much. These implants are able to orchestrate
cellular adhesion, differentiation, tissue formation and vascularization.
Moreover, they are designed to control the construct's resorption rate
and provide delivery of multiple drugs and/or proteins. However,
despite all the progress, it remains difficult to predict successful clinical
outcomes. In particular, discrepancies between in vitro and in vivo
results have frustrated our ability to predict the success of newly devel-
oped complexities for bone defect healing cell based ATMPs. This might,
at least in part, be caused by unphysiologically in vitro culture condi-
tions. The currently used protocols do not account for important
influencers of bone healing such as blood clot formation, inflammation,
and molecular complexity of the various bodily fluids. Moreover, bone
defects represent a dynamic environment in which the ATMP not only
is required to stimulate multiple processes simultaneously, but also
perform these functions in a spatiotemporally timed manner. This
entails that the biomaterial design criteria should not solely be aimed
at providing ideal characteristics upon implantation, butmore so to pro-
vide distinct microenvironments throughout the healing process. In-
deed, increasing amounts of evidence support that incorporation and
spatiotemporal control over e.g. inflammatory pathways can play a
key role in guiding the regenerative response of ATMPs andhave thepo-
tential to significantly improve the clinical outcome [40]. Besides
developing and modifying various biomaterials to mimic the physico-
chemical characteristics of natural bone tissue, scientists have also con-
tinually investigated the potential of biomaterials made of bone tissue
extracts. Specifically, much attention has been given to create functional
bone tissues by revitalizing ECM-derived fromdecellularized bones [41]
or in vitro cultures [42]. This approach has the advantage that it is
fundamentally based on biologically natural bone to induce tissue
regeneration. Indeed, these implants proved to be osteoconductive
and osteoinductive. Bone allografts and demineralized bone matrix
are the long-standing examples of decellularized organs or extracellularmedicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
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mineralized collagenmatrix (for direct ossification) [43] andmineralized
hypertrophic cartilaginous template (for endochondral ossification) [44]
have been reported to possess great potential for bone regeneration
applications [45]. However, the effect of various decellularization proce-
dures on the biological outcomes as well as their safety remain challeng-
ing topics, especially regarding their prospective ATMP approval by the
regulating bodies [46,47].
4.2. Cells: from matrix deposition to orchestrating tissue formation
The choice in cell source has a profound impact on the clinical
outcome of the cell based ATMP. Important selection criteria are
their bone forming capacity, availability in sufficient quantity, non-
immunogenicity and non-tumorigenicity. The naturally occurring
bone forming cell of our body, the osteoblast, can be isolated via both
enzymatic digestion of and outgrowth from bone fragments [48]. More-
over, osteoblasts are plastic adherent and can be grown and expanded
in vitro. It therefore would seem logical that the use of these cells
would be the gold standard and their use widespread. However, only
a limited amount of studies report the use of these primary cells. This
is mainly caused by their limited accessibility, self-renewal capacity
and heterogeneous nature, which varies between donor and anatomical
origin of the original bone fragment [49]. Regardless, the use of osteo-
blasts in cell based ATMPs remains considered promising when
sufficient amounts of cells can be obtained. For in vitro analysis,
however, much research has relied on the use of osteoblastic-like cell
lines such as MC3T3-E1, MG-63, hFOB, U2OS and SaOs-2 [50]. Due to
the origin and modified nature of these cell lines, they are able to con-
tribute to our current understanding, but are not suitable for clinically
relevant cell based ATMPs.
Instead, the use of a myriad of osteogenic stem cells has been
pursued with great enthusiasm. These include induced pluripotent
stem cells, pluripotent embryonic stem cells and multipotent stem
cells (MSCs) from a wide range of connective tissues [51]. Of these,
adultMSCs e.g. derived from the bonemarrow, adipose tissue or perios-
teum are themost commonly used. It is assumed that the organ specific
ontogeny of these cells contribute to their progenitor function and ther-
apeutic regenerative capabilities of bone tissue. The challenge in using
these cells lies in an expansion step, which for most cell based ATMPs
is required. Adult MSCs have a limited proliferative capability and
their expansion coincides with a progressive loss in differentiation
capability [52]. This drawbackmight bemitigated by optimizing culture
procedures via the use of different culture substrates such as coatings
[53] or biofunctionalizedmicrocarriers [54]. Alternatively, cells with un-
limited proliferative capacity and unhampereddifferentiation capability
are considered. From this perspective, embryonic stem cells and more
recently induced pluripotent stem cells have been explored. These
pluripotent cells have indeed been proved to effectively form new
bone in vivo [55,56]. However, until all constraints including ethics,
cell fate stability, safety and tumorigenicity have been solved, the
expedient clinical translation of these cells remains uncertain.
Multipotent and pluripotent stem cells, unlike osteoblasts, can form
bone via both intramembranous and endochondral ossification [57].
Advantageously, current “chondrogenic” protocols efficiently drive
stem cells into becoming hypertrophic chondrocyte-like cells [58,59].
Implanting such a cell based ATMP would mimic the natural bone
healing process for which the body provides multiple well organized
spatiotemporal stimuli [60]. This includes growth factors, oxygen ten-
sion, nutrient availability, and biomechanical loading, which together
induces cartilage degradation, vascularization, cellular invasion and
finally bone formation. Moreover, the chondrogenic differentiation of
stem cells is argued to more proficiently deal with stresses caused by
low levels of oxygen and nutrients. This is a strong advantage for both
the upscaling of ATMPs to clinically relevant sizes as well as their
in vivo survival during their pre-vascularized phase.Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.10.025An exciting and relatively new approach to incorporate biological
complexity in a simple manner is the co-culturing of bone forming
cells with additional differentiated supporting cells. This allows the
mitigation of drawbacks of singular cell types and can even induce syn-
ergistic behavior. For example, osteoblasts are only available in limited
quantity, which can be remedied by implanting these cells in the
presence of a majority of MSCs. This not only required less population
doublings of the osteoblast, but promoted and stabilized the osteogenic
phenotype of the MSCs and thus improved bone formation [61]. The
most commonly reported co-culture for bonehealingATMPs is between
bone forming stem cells and endothelial cells [62]. In these cultures
synergistic effects are observed in microvascular formation [63], vascu-
lar stabilization [64], MSC proliferation [65] and possibly osteoblast
function [66]. Due to the promising findings of these co-cultures, some
research groups have started to investigate the potential of triple cell
co-culture strategies for the evaluation and design of bone healing
ATMPs [67]. Moreover, it is of importance thatmany of these synergistic
co-culture phenomena have been reported to be derived from the
expression of trophic factors in numerous systems. These include
vascular endothelial growth factor, bone morphogenetic proteins and
fibroblast growth factors [68–71]. All of these factors are known to
play an important role in the natural bone healing process. Therefore
they are prime candidates for the – currently largely unelucidated –
underlying signaling mechanisms for the improved bone formation in
co-cultured ATMPs.
In summary, although ATMPs containing co-cultured cells might in-
tuitively seemarduous, indirect and complex, theymay in fact represent
a “simple”method to orchestrate the bone formation process on multi-
ple levels by allowing the body to follow its natural mechanisms.
4.3. Growth factors: frommedium supplement to spatiotemporal instructor
The biological performance of cell based ATMPs is typically
enhanced by the addition of stimulating compounds such as growth
and differentiation factors. In bone repair strategies, growth factors
have traditionally been chosen to expand cells in vitro, stimulate the
osteogenic phenotype or attract blood vessels. However, many of
these proteins are overlapping in their functions (Supplementary
Table 2). All of these proteins also contain more broad functions. In
fact, most of these proteins also regulate cell proliferation, migration
and apoptosis. As such, many growth factors distinguish themselves
via their stimulation efficacy, rather than via providing a unique biolog-
ical function.
For bone healing, the most investigated proteins belong to the bone
morphogenetic protein (BMP) family. The most commonly explored
family member is BMP2, closely followed by BMP7/OP1. Notably, both
of these proteins have been approved by the FDA for several clinical
bone treatments such as spine fusion and non-healing long bone frac-
tures. Several other BMPs have also been explored for their bonehealing
capacities and demonstrated to possess favorable qualities. For instance,
BMP6 also readily allows bone formation, but unlike BMP2 does not in-
duce apoptosis in mature osteoblasts [72]. In fact, BMP6 was demon-
strated to protect from apoptosis, at least in MSCs [73]. Furthermore,
BMP6 was demonstrated to more effectively form bone than BMP2
[74]. Yet BMP6 has not been reported to be used in any clinical trial
nor has received clinical approval. Although exemplary, this underlines
the need for well controlled studies that compare multiple bone
forming growth factors. This will allow more quantitative comparisons
of growth rather than the more common approach of identifying a
certain biological potency of a growth factor of choice.
Regardless, human clinical trials have emphasized the efficacy of the
use of BMPs. For example, the use of BMP2 in open fractures of the tibial
shaft reduced the frequency of secondary interventions, overall inva-
siveness of the procedures, infection rate in patients and accelerated
fracture and wound-healing [75]. Although these studies represent
significant advances in medical care, caution is still needed as the usemedicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
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tion, BMP2-antibody development, soft tissue swelling and potentially
even cancer induction [75,76]. It is of note that current clinical trials
rely on supraphysiological levels of these proteins ranging in the order
of milligrams per milliliter instead of nanograms per milliliter. Indeed,
it is not unlikely that these adverse effects are actuated by the use of
supraphysiological dosages.
Several approaches have been explored to reduce the amount of
growth factors required to heal bone defects. Most recently, an exciting
advance was reported in which growth factors were engineered to pos-
sess exceptionally strong bindingproperties to extracellularmatrix [77].
Specifically, the highly effective matrix binding sequence of placenta
growth factor-2 was fused with growth factors such as the granular
tissue forming platelet-derived growth factor (PDGF), the angiogenic
vascular endothelial growth factor (VEGF) and the bone forming
BMP2. This approach reduced the required amount of growth factors
to heal bone defects with two orders of magnitude. Likewise, BMPs
have been engineered to become resistant to the inhibiting function of
antagonists such asNoggin [78] or have reduced binding to extracellular
matrix and thus improved solubility [79].
More traditional approaches to improve growth factor performance
while reducing the required amount have relied on the cumulative or
even synergistic effects between distinct growth factors. For example,
the effective BMP2 dosage could be lowered when combined with
stromal cell-derived factor 1 (SDF1) [80] or fibroblast growth factor 2
(FGF2) [81]. This approach of combining multiple growth factors also
yields valuable insights in their performance in more complex environ-
ments that perhaps more closely resemble the fracture healing process.
For example, VEGF protects endothelial cells from apoptosis, but con-
tributes to endothelial apoptosis in the presence of transforming growth
factor beta (TGFB). Moreover, BMP6 is a positive stimulator of the for-
mation of hypertrophic cartilage, but the addition of FGF2 abolishes
this effect [82]. Besides providing anecdotal evidence on the behavior
of the selected growth factors, these studies also accentuate another
equally important perspective: in vitro studies that observed effects
using single protein approaches cannot guarantee predictable in vivo
behavior. This is especially true in awound healing process such as frac-
ture healing where protein expression is regulated in a spatiotemporal
manner.
Delivery of growth factors can be achieved in several manners that
include unbound, coated on the implants surface, bound within the
implant for controlled delivery and coded within the cells via gene de-
livery. Of these, it could be reasoned that controlled delivery could be
the optimal method as it can be tailored to match the dynamic healing
process. However, current clinical trials have typically relied upon un-
bound growth factors, which is characterized by a burst release and
followed by rapid clearing. This requires high dosages and does not
allow for control over its release. It is therefore expected that the clinical
outcome of cell based therapies can be further improved in a straight-
forward manner by using more sophisticated growth factor delivery
systems.
5. Upcoming technologies: simple solutions for introduction of
biological complexity
Current cell based therapies can be significantly improved via the in-
corporation of existing and widely explored approaches and technolo-
gies. However, even upon implementation, several key issues will
remain suboptimal. These issues include the development of ‘smart’
scaffolds that dynamically adapt to the healing process, capabilities
to create, in vitro, biological structures at both the micro- and macro-
level and methods to allow rapid vascularization and anastomosis
of the implant. To achieve this, we require state-of-the-art or even
novel enabling technologies to provide the biological complexity to
improve the clinical outcome of cell based ATMPs in a relatively simple
manner.Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
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Matching a cell based ATMPwith the natural dynamics of thewound
healing process is of the utmost importance. It is arguably the greatest
opportunity to improve the modern day implants. In order to accom-
plish this, cell based ATMPs must present stimulating instructions in
both the appropriate combination and proper time scale. Moreover,
the implant should regulate a plethora of biological processes, which in-
cludes chemotaxis, proliferation, differentiation and angiogenesis. Over
the last decades many strategies have been developed that can aid in
achieving this goal. Specifically, several hydrogels have been developed
that are able to respond to their environments and present stimuli on a
cell's demand. These biomaterials can contain protease sensitive sites,
tunablemechanical properties, cell adhesionmolecules and various sig-
nalingmolecules such as growth factors [83]. The sequential release and
presentation of growth factors can be determined by the manner in
which they are incorporated into their biomaterial (Fig. 3). Specifically,
growth factors can be incorporated in anunbound, physically entrapped
or covalently bound fashion. When unbound, the growth factor will be
released in bulk. This is typified by the generation of a steep concentra-
tion gradient, which is rapidly cleared. This type of release can be ideal
for initial short term stimulations. Whenmore prolonged growth factor
presentation is desired, the protein can be physically entrapped, or
alternatively, bound by affinity [84]. This approach ensures that the pro-
tein is not lost to the ATMP by unhindered diffusion. Moreover, when
physically entrappedwithin a controlled release vehicle e.g. nanoparticles
ormicroparticles, the release can even be further fine-tuned. By covalent-
ly binding the growth factor to a biomaterial via a cleavable linker, the
growth factor can be delivered on a cell's request [85]. Advantageously,
this can be coupled to behavioral features that only occur in a later
stage of the healing process. By combining these growth factor release
strategies, cell based ATMPs are expected to directly interface, react
with and steer the wound healing process. However, whether such a
complex cell based ATMP can be designed to be sufficiently simple to
allow clinical translation is yet to be proven.
5.2. Bottom-up tissue engineering: providing spatial organization
Supreme cell based ATMPs closely mimic the natural healthy tissue
by imitating their compositional and organizational structure. Current
implants are able to resemble the natural composition, but largely lack
the natural organizational structure. Recent technological develop-
ments allow the formation of micrometer sized building blocks of
biomaterials and/or cells [86,87]. Subsequently these building blocks
can then be used in a bottom-up approach in which they are assembled
into clinically sized implants [88]. To accomplish this, various tech-
niques have been explored, which function on distinct length scales.
Assembling single cells into micro-aggregates can be used to recapitu-
late the creation of (stem) cell niches [89]. This property is due to the
differential adhesion of cells and is therefore applicable to a wide
range of cell types and tissues. To create larger structures micrometer
building blocks can be assembled into a larger and evenmore structured
assembly. This can be achieved using a range of methods (Fig. 4). The
most commonly used techniques is the use of newly added cells to
bind micro-aggregates and micro-objects together [90]. Lock-and-key
structures that minimize the surface free energy between the object
phases can also be used for the same purpose [91]. An exciting develop-
ment that allows novel possibilities is the use of the specific bonding of
DNA base pairs [92]. Recently, this technique has been used to glue dif-
ferent micro-materials together in an instructed and organized fashion
[93]. This can in theory allow for the formation of highly organized
and structured implants due to near infinite amount of possible combi-
nations and specificity of these bonds. However, the technology is
currently still challenged with difficulties in creating clinically sized
constructs. Alternatively, microfluidic devices have been demonstrated
to be able to create complex structures from prefabricated micro-medicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
Fig. 3. Schematic representation of stimuli release strategies.
Adapted from [196].
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does not easily permit the up scaling into the third dimension. Instead,
micro-materials can reach clinical dimensions by fusing them within a
mold using secondary crosslinking steps or via the cell's own adhesive
properties [95]. Even larger and more complex implants are expected
to be produced with the upcoming revolutionary technology of three
dimensional printing of cells [96]. Themain advantage of this technolo-
gy is its inherent capacity for patient customized production cell based
ATMPs. For example, perfectly fitted implants can be created based on
a three dimensional computed tomography image of the patient's tissue
defect.
Together these bottom-up approaches have the potential to produce
cell based ATMPs with some of the complex hierarchical organizational
structures that are found in native tissues. However, it remains to be
demonstrated that creating these structures before implantation has a
distinct clinical advantage. Providing ATMPs with sufficient temporal
cues to steer the natural wound healing to create these organizational
structures in vivo might represent an equally effective yet much more
clinically accessible approach. As such, it might be argued that these
purely bottom-up approaches might prove too complex to allow for
wide spread clinical translation. Instead, a hybrid approach that is
neither truly top-down nor bottom-up might prove the most effective
ground for the introduction of a minimal amount of structural organiza-
tion. Specifically, this approachwould focus on the incorporation of a dis-
tinct structural component into an otherwise top-down construct. This
can be of particular relevance to the (pre)vascularisation of the implants.Fig. 4. Exemplary approaches of bottom-up approaches able to provide spatial organization on
blies to preformed moldings.
Adapted from [91,94,95,197].
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Integrating with the host is an essential aspect of cell based ATMPs.
Creating functional anastomosis between the implant and the host's cir-
culatory system is important for the exchange of oxygen and nutrients
as well as for the clearance of waste products. Moreover, it also plays a
vital role in the remodeling andmaturation of the implant. For example,
implants of hypertrophic cartilage are used as a tissue intermediate to
produce endochondral bone. An essential element to achieve this is
the infiltration of bone forming cells. Vascular invasion allows the effi-
cient delivery of these cells into the implant [97]. Moreover, the lack
of vascularization in implanted cell based ATMPs results in the expres-
sion of angiogenic proteins that recruit the host's vasculature towards
the implant [98]. In turn this alleviates hypoxic stress, which presents
the implant with an alteredmicroenvironment that can result in behav-
ioral adaptation. For example, hypoxic stress is known to promote car-
tilage formation, while alleviation of hypoxic stress induces terminal
differentiation in the cartilage [99,100]. In consequence, the vasculariza-
tion strategies of cell based ATMPs are expected to balance cell survival
with the behavioral consequences of the temporally desired oxygen
tension and nutrient availability.
Endowing cell based ATMP with appropriate angiogenic properties
can potentially be achieved in various ways. These cover all facets of
the implant including growth factors, cells and biomaterials. This gener-
ates a large degree of freedom in the design and optimization of the
angiogenic properties of the implant. The most commonly used growthvarious scale lengths ranging from co-cultures, lock-and-key structures, organized assem-
medicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
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the timely release of angiogenic proteins – often in combination with
controlled release of osteogenic proteins – has demonstrated rapid
vascularization of the implant followed by improved bone healing
[101]. The inclusion of angiogenic cells can contribute to blood vessel
formation in several ways. The most intuitive is the contribution of the
cells to the generation of new vessels. However, they can also recruit
newblood vessels by acting as trophicmediators,which amongst others
secrete angiogenic proteins [102]. Finally, the implant's cells can act as
stabilizers of newly formed vessels by behaving as pericyte-like cells
[103]. Although relatively mature endothelial cells are mostly used for
these purposes, recent studies have highlighted the possibility to use
predifferentiated progenitor cells as an effective alternative [104].
To allow the penetration of the recruited vasculature, the biomateri-
al has to provide space for the invading/developing blood vessels. As
such, the biomaterial has to contain either sufficiently large pore sizes
or allow remodeling. The incorporation of peptides or proteins that
allow adhesion and/ormigration has been repeatedly reported to accel-
erate the vascularization [105]. However, the current integration of this
valuable knowledge into clinically used cell based ATMPs has remained
negligible.
Many of the currently explored strategies have enhanced the vascu-
larization of implants. However, the speed of the biological process of
vascularization is finite. This has direct and dire consequences for
upscaling the implant's size as it is likely that in sufficiently large
implants the cells in the core of the cell based ATMPs undergo apoptosis
or necrosis due to starvation. To circumvent this, several techniques
have recently been developed to provide implants with a vascular
network before implantation (Fig. 5). Advantageously, this allows circu-
lation of the blood supply throughout the entire implant upon acquiring
thefirst anastomosis. This can be achieved using endothelial cells such as
human umbilical vein endothelial cells or outgrowth endothelial cells to
create, in vitro, a three dimensional prevascularized network within the
implant [106,107]. In addition, biomaterial-based approaches have re-
cently been explored. Aligned hydrogelfibers optimized for angiogenesis
can function as ‘highways’ for the invading blood vessel. Moreover,
by loading these fibers with endothelial cells the implant can form a
prevascular network [108].
Blood vessels can also be embedded into the cell based ATMP during
the biofabrication process. For example, implants containing hollow
vessels that are surrounded with a bilayer of umbilical vein smooth
muscle cells and fibroblasts using three dimensional printing of cell-
laden biomaterials [109]. Alternatively, the cell laden implant can be
formed around a complex prevascular network of a biocompatible
sacrificial template. These templates can be produced using e.g. thermal
extrusion of a template with a three dimensional printer that, in turn, is
incorporated in a second biomaterial, which can then be sacrificed to
reveal a complex prevascular network [110]. Although all of these
approaches are exemplary demonstrations of the progression withinFig. 5. Exemplary approaches of providing cell based ATMPs with a prevascular network ran
templates of complex three dimensional vascular structures.
Adapted from [108–110,198].
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value via clinical trials still strongly lags behind.
6. Modeling: predicting successful approaches
A plethora of novel developments has been introduced to improve
cell based ATMPs as presented in this review. However, history has
evidenced that only a fraction of these will actually be translated into
clinically useful treatments. This is in part caused by the off-set of the
intensive investment of both time and money that is required to bring
new developments from bench to bedside. In addition, it is a tempting
and understandable pitfall to perpetually postpone clinical translation
of scientific discoveries as future improvements and discoveries are
expected to result in even better potential clinical outcomes. For this,
advanced modeling can be considered an ideal tool to both predict the
effect of new strategies and semi-objectively forecast when a technolo-
gy is sufficiently developed to proceed into clinical translation (Fig. 6).
When exploring this road, it is of importance to appreciate that even
the simplest solutions described in this review rely on complex biolog-
ical processes. It not only integrates the different components of the
ATMP, but also their interactions with the host environment post-
implantation. The mechanisms of action for many of these ATMPs are
not yet fully elucidated which means that optimization of treatment
strategies largely remains a process of trial and error. In classical engi-
neering disciplines, an indispensable step in the design and implemen-
tation of novel solutions is the computational, in silico, step. For
example, a real-life prototype of a new car is only made after it has
been thoroughly tested and optimized in silico. Over the last decade,
this in silico step is slowly finding its way to the design of medical prod-
ucts [111,112] and more recently also to the field of cell based ATMPs
[113–115]. Typically, computational approaches are largely described
by their spatial/temporal scale and their incorporated underlying infor-
mation. For the latter, this can range from purely hypothesis-based
mechanistic models, which starts from the hypotheses on the mecha-
nisms of action [116,117], up to purely data-based empirical models
by using advanced statistics to uncover predictive relations in data
sets [118,119]. Each of these model types has its advantages and disad-
vantages and its appropriateness dependent on the question at hand.
Regardless, in silico modeling has the potential to contribute to the
design of “goldilocks” ATMPs. It can specifically contribute to three
major aspects of the ATMP design cycle: the product, the process and
the interaction with the host.
The biological state of the cells – within the ATMP – can be investi-
gated by studying in silico their underlying regulatory network. Statisti-
cal approaches on the one hand allow one to uncover biomarkers that
are hidden in the large high throughput data sets generated by state
of the art experimental techniques [119,120]. On the other hand, mech-
anistic approaches allow the investigation of the interaction between
specific pathways in more spatiotemporal detail [121,122]. Combined,ging from tube-like networks, guiding biomaterials, embedded capillaries to sacrificial
medicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
Fig. 6. Exemplary in silico models of bone regeneration on various scale lengths ranging from gene regulatory networks, single cell models, models of neotissue growth inside scaffolds
during bioreactor culture to models of bone fracture healing (bone density in black, blood vessels in red).
Adapted from [199–202].
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tification of the precise state of the cells within the ATMPs and contrib-
ute to optimized culture conditions to push or keep cells in a desired
state [123]. Besides the ATMP's cellular component, computational
models are also used to investigate and optimize the cells' (biomaterial)
microenvironment in terms of mechanics [124–126], mass transport
[127–130], scaffold topology [131–134] and composition [116].
Bioreactor cultures represent another facet in which computational
models can provide insight in themechanisms, elucidate discrete exper-
imental observations and control for manufacturing variability of the
cell based ATMPs. In silico design of appropriate bioreactor protocols
leads to optimized cell seeding [135,136] and cellular differentiation in
3D porous scaffolds [123]. Furthermore, the maturation of the grown
cell based ATMPs can be captured and even predicted by computational
models using basic mechanistic rules on the influence of substrate
geometry and the microenvironment [137–139]. After validation,
these models become an inherent part of the bioreactor control loop
and thus allowing active control over the ATMP quality.
Upon implantation of the ATMPs, the interaction with the host will
determine the success or failure of the treatment. Taking the step from
in vitro to in vivo can be facilitated by preparatory in silico studies
allowing to a priori investigations of the effect of e.g. scaffold dissolution
[132], mass transport and blood vessel formation [136,140]. Similarly,
translating preclinical results in animal models to the patient can bene-
fit from an intermediate in silico step to study the effect of changes in
implant dimension, and cell characteristics. Additionally, changes in
model variables and/or parameters allow further elucidation of the
etiology of structurally or genetically compromised healing situations
[141,142]. Together thesemodel systems can rapidly provide predictive
information that can subsequently be used to adjust the ATMP design.
This is expected to play an important role in overcoming patient-
specific hurdles.
Currently, the use of computational models in clinical routine is still
limited. However their usage as a research tool in both academia and
industry is growing steadily and progressively. Importantly, there is
ample precedence of the contribution of such models to biomedical
breakthrough. Specifically, research fields investigating cancer and car-
diac disease have already benefitted from computational models. In fact
they are directly responsible for the development of novel treatment
strategies,which are currently being tested in phase I and II clinical trials
[121]. For treatment of diabetes, the FDA has approved the use of
computational models as valid preclinical evidence for the dossier of
implantable insulin pumps [143]. The importance of in silico modeling
in aiding the translation of fundamental findings into effective cell
based ATMPs is further explicitly underlined by the FDA in ‘priorities
for regulatory science formedical products’. Moreover, the ever increas-
ing available computational power is expected to allow for the calcula-
tion of progressively more complex computational models in real-time,
nurturing the further exploitation of in silico models in the design and
prediction of successful cell based ATMPs.Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
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The amount of clinical trials involving cell based therapies and FDA
approved commercially available cell based ATMPs progressively
increases. This is a strong indicator that cell based ATMP therapies are
maturing and indeed might still deliver on their promise to revolution-
ize healthcare [144,145]. In order to facilitate their clinical translation,
ATMPs will need to be manufactured in cost-effective, scalable and
robust bioprocesses. Moreover, the ATMPs should not only meet the
requirements of regulatory bodies in terms of clinical efficiency and
safety, but also in terms of their quality control and goodmanufacturing
practice (GMP) [146,147]. Currently, stem and progenitor cell isolation,
expansion and differentiation as well as neo-tissue formation consist of
the conventional series of manual techniques. This artisan approach is
heavily dependent on operator expertise and is thus suboptimal as it
contains high risk of processing inconsistencies and is prone to contam-
ination [148,149]. Furthermore, the manual assembly and handling of
the cell based ATMP is likely to cause variation in cell number, pheno-
type, extracellular matrix content/morphology and thus consequently
in in vivo behavior and clinical outcome. The replacement of these
artisan approaches with robust automated bioprocesses will constitute
an important step towards the robust development of industrially
reliable cell based ATMPs.
Bioreactors are expected to play a crucial role in this automation in at
least two ways (Fig. 7). Firstly, they can controllably isolate cells from a
biopsy and subsequently enable their upscaled expansion to obtain
sufficient cell numbers in a highly reproducible manner [150–153].
This can be achieved via microcarrier based bioreactor systems such
as stirred tanks [146,154] and wave bags [155]. These systems have
been successfully used for human mesenchymal stem cell expansion.
Moreover, aggregate expansion has also been achieved in shake
flasks [156] as well as in hollow fiber systems [157]. These systems
have the important characteristic that they are able to expand progeni-
tor cells, while optimally retaining their differentiation potential
[152,158–161]. Furthermore, several commercial stem cell expansion
systems have recently entered the market providing GMP platforms
with enhanced reproducibility and scalability such as the Terumo
Quantum® hollow fiber and the single-use Integrity Xpansion™
multiplate bioreactor system. Although these systems are intuitively
more complex than conventionalmanual procedures, they in fact repre-
sent a facilemeans to simplify cell basedATMPproduction protocols in a
controlled and reproducible manner.
Secondly, bioreactors provide a unique aid to develop structurally
defined and functionally effective complex engineered ATMPs at the
patient-scale [162–164]. A broad range of bioreactor systems has been
described to date in literature for the controlled production of three
dimensional bone forming constructs [165–168]. Indeed, several
bioreactor-generated cell based ATMPs that successfully followed the
intramembranous [169,170] and/or endochondral bone formation
[171] mechanisms have been reported. Overall, cell based ATMPsmedicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
Fig. 7. Exemplary approaches of enabling bioreactor strategies to advance themanufactur-
ing of cell based ATMPs. Modular approaches specialized for either scaled cell expansion
and subsequent controlled maturation of the implant could facilitate cost-effective
translation.
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cell content and extracellular matrix deposition [172–175], increased
mineralization [166,176] and osteogenic differentiation [177,178] as
compared to static setups. In addition, the use of oscillatory flow has
been shown to further improve the spatial distribution of the formed
neotissue within the scaffold [179]. The responsiveness of cells to the
flow environment may be used to actively orchestrate cell based
ATMPquality characteristics towards the desiredfinal state byminimiz-
ing random events during culture and thus prevent batch failures.
Regardless whether a bioreactor system is used for expansion or
construct maturation, its reliability will depend on the bioreactor's
steady-state control of the bioprocess. This is governed by the predic-
tion and/or measurement of parameters including flow rate/shear
stress, dissolved oxygen tension, pressure drop, nutrient supply
minimizing complexity and variability of the environment that the
cells will experience [180,181]. Ideally, this information is provided by
non-invasive online monitoring modalities that are incorporated in a
closed bioreactor system. This will allow the follow-up of the quality
characteristics of manufactured ATMPs continually during the various
phases of its production. Such methods have already been employed
for the on-line determination of cell content in bioreactors of metabolic
activity [182] oxygen consumption [183] and heat production [184].
Although these approaches allow relatively simple measurement of a
high amount of specimen, they only provide data on the ATMP average.
In order to obtain more spatially insightful and accurate information,
the use of imaging tools such as micro-computed tomography [173] or
fluorescent imaging [185] can provide extensive spatial information at
the tissue level. However, such information comes at the cost of the
requirement of dedicated expensive equipment, which is unlikely to
prove cost-effective in an upscaled ATMP production process.
A crucial aspect towards the direction of controlled and automated
cell based ATMP production is the development of novel methods to
incorporate existing technologies into bioreactor setups to allow online
readouts of relevant biological parameters such as gene expression, pro-
tein production, cell surface antigen expression and metabolic activity.
Ultimately, this information should not just be used to characterize
the ATMP, but more so to actively steer its production process. The
development of data based algorithms will be able to process on line/
real time allowing for automatic adjustment of bioprocess parameters
based on variations of the immature ATMP's behavior [186]. Such
an approach will enhance our understanding of the highly complex
TE bioprocesses and allow the development of predictive models for
in vitro cell behavior. In the end, this is expected to play a crucial rolePlease cite this article as: J. Leijten, et al., Cell based advanced therapeutic
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ible high quality cell based ATMPs.
8. Cost effectiveness: from lab-promise to specialized niche market
A final consideration in the development of cell based ATMPs is
related to its cost. Firstly, the product's costs should be compensated
by its effectiveness in terms of clinical outcome. Secondly, the product
should fit within the social health care system to receive potential
reimbursement. Hence as part of a cell based ATMP development and
translation to the commercial market, one needs to have a clear over-
view and understanding of the complete value chain. Moreover, these
boundary conditions should be taken into account as early as possible
in the R&D process. This holds particularly true in the novel approaches
that aim to incorporate complex (artisan) techniques to alleviate the
simplicity induced limitations of the current products. In essence, a
product is expected to add value to the current possible clinical treat-
ment regimes, while maintaining or improving the cost-effectiveness.
A potential clinical setting where cell based ATMPs for bone repair
can add value is the treatment of non-unions of long bones. In general,
musculoskeletal conditions place a worldwide burden on the health
care system. A large part of this significant healthcare expense is attrib-
uted to their complications, predominantly non-unions [187]. It is ex-
pected that novel therapies can contribute to the mitigation of this
health care burden. For example, the health economics of the recon-
struction of a bone defect versus an amputation are on the long term
positive for the reconstruction (€350k health care cost reduction)
despite the fact that the actual implant, surgery and short term
follow-up are more expensive (+€10k) [188].
It is reasoned that the chance on successful market entry can be
enhanced by initially aiming the cell based ATMPs for bone repair
towards an orphan non-union. Specifically, orphan diseases that com-
plicate fracture healing and leading to non-unions for which currently
no effective treatment exists. This permits a relatively simple market
entry as its unique selling proposition provides the ATMP with the op-
portunity to generate compelling clinical proof at a premium price
(€50–100k), although be it with a low number of patients (~100 cases
per year). This period can be used to advance industrial and clinical
processing and thus reduce the cost-per-product thereby also allowing
the scale outmanufacturing to enable biggermarket supply. Then, a sec-
ond (autologous) product can focus on a larger non-orphan market for
non-unions (~20,000 cases per year) as it can bemarketed at a lowered
price (€10–50k), while maintaining cost-effectiveness. Finally, a third
product, based on further technological and stem cell advances, can be
an allogeneic cell based ATMP that targets the main market of non-
union preventions and usage as first line (off-the-shelf) treatment.
This market has the advance of large patient numbers (~300,000 cases
per year), but is a price driven market with direct competition with
other bone substitutes such as autograft, BMP devices and synthetic
bone fillers, thus requiring a competitive price (€1–10k) [189].
The transition from lab experimentation, to small nichemarkets and
eventually to large-scale commercial production of cell based ATMPs is
hampered by a lack of robust and cost-effective manufacturing and
clinical delivery processes that can deliver regulatory-compliant
and safe cellular products [190,191]. Therefore, the development of
dedicated and validated enabling technologies, including the different
types of bioreactors, is of great importance for viable and sustainable
cell based ATMP manufacturing [192]. It is estimated that the introduc-
tion of automated systems, would both decrease the capital and
operation expenditure approximately by 50%, mainly due to decreased
amounts of FTEs and building space. In particular, the cost of a bioreac-
tor grown cell based ATMP for bone repair – based on currently
available technology – is estimated within the range of $10,000 to
$15,000 [163], thus finally resulting in premiumprice commercial prod-
ucts. Furthermore, it might be argued that novel production processes
are required that lower costs per ATMP to allow sufficiently competitivemedicinal products for bone repair: Keep it simple?, Adv. Drug Deliv.
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solutions for large amounts of patients.
From this perspective, it can be concluded that clinical and commer-
cial entry of cell based ATMPs for bone repair requires start to finish
assessment and control of its cost effectiveness as opposed to the
more common focus on improving the clinical outcome as compared
to the current golden standard. Moreover, this will govern the targeted
market(s), which will allow the mid- and long-term acceptance of
becoming an established, routine and possibly even preferred therapeu-
tic approach.
9. Concluding remarks
Regenerative medicine has not yet made true on its promise to
revolutionize our health care system. Only a few cell based ATMPs
breached the chasm of bench-to-bedside translation. Unfortunately,
those that made it have mixed clinical outcomes and depend on the
patient profile. A main underlying factor is the elementary and uncom-
plicated approach of these now bed-side therapies. Such cell based
ATMPs typically consist of cells that have undergone no targeted selec-
tion with or without biomaterials that are only rarely modified, in the
presence or absence of growth factors that are incorporated using
unbound strategies. In stark contrast, the developing bench-side cell
based therapies are stereotyped by ever increasing complexity in the
formof combinations,modifications, preselections and preconditionings.
Promisingly many of these complexities are not aimed to stimulate the
tissue formation in an autonomous manner, but rather to remedy
ailments in a collaborative effort between the implant and the body's
own natural healing processes. This might prove an effective approach
in some specific indications to relief the implant's current simplicity
induced limitations without over-engineering the product. Thus this
approach can potentially result in a cost-effective ‘goldilocks’ cell based
ATMP for bone repair that is neither too simple nor too complex.
Although a plethora of promising novel cell based therapies has been
designed and tested, nearly all of the bed-side worthy approaches have
remained “stuck” in the development pipeline. One possible explana-
tion for this is the paradox of choice, where a larger amount of choices
leads to higher tendency to indecision. Specifically, in the last decades
bench-side developments have surpassed each other in a relentless
pace. This has lead to a myriad of highly competitive choices of
approaches. Most of these studies compare their novel approach only
to the current golden standard, but not to competitive alternative
bench-side approaches. Although this is surely an understandable
strategy, it does not enable direct comparisons on the state-of the-art.
Specifically, although we possess reliable quantitative analysis tech-
niques, the variability between the distinct experimentation protocols
between different laboratories obscures their direct comparisons.
Studies experimentally comparing multiple promising ATMPs are
therefore of paramount importance. They objectively identify the
prime candidate(s) for clinical translation, which could be expected to
result in superior clinical outcomes as compared to themore subjective
inventor driven translation. In addition, harmonization, predictability
and clarity of the various legislative frameworks, reimbursement
scheme's and preclinical efficacy as well as meticulously described
product characterization, robust integration of innovative systems and
manufacturing with cost of goods in mind will expedite the ‘time-to-
market’ of these candidate ATMPs [193]. Furthermore, the current lack
of understanding regarding the reasons of failure of investigated
ATMPs further obscures the effective development of successful
AMTPs. Many academic studies are designed as proof-of-principle ex-
periments and rarely provide robust prospective studies in sufficient
numbers to test for clinical outcomes and their relevance to the patient.
In contrast, themany clinical studies that have been performed, and are
ongoing, are sponsored by for-profit companies and many of these
studies and/or their failures are either not reported or rarely discussed
in detail, in this young field. Accessibility and transparency of data,Please cite this article as: J. Leijten, et al., Cell based advanced therapeutic
Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.10.025especially negative data, are consequently of high priority in the selec-
tion of developing technologies that can fuel the development of new
and clinically successful ATMPs.
Comparative studies and a better understanding of the mechanisms
of action can aid on an additional level to bringing the next-generation
of cell based ATMPs closer to the clinical market. In particular, most
translational research takes place on approaches that have previously
been approved for various conditions by the regulating bodies, regard-
less of whether current science/literature supports that as the optimal
choice. For example, research supports specific advantages of BMP6
over BMP2, while the latter receives near undivided translational
attention. Truly objective comparative research enables the rise of new
champions to break regulatory ground and obtain approval for the use
of the most promising combinations rather than the most readily trans-
lational combinations. Indeed, certain steps are already currently been
taken – e.g. the attempt to obtain approval for BMP6 – and are expected
to result in cell based ATMPswith improved clinical outcomes. Together,
‘goldilocks’ cell based ATMPs that are designed based on objective com-
parative research and are produced using cost-effective manufacturing
processes might yet deliver on their original promise of revolutionizing
the western health care system.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.addr.2014.10.025.
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